Wave Life Sciences’ stock surged on Wednesday after the company announced positive proof-of-mechanism data from its Phase 1b/2a RestorAATion-2 study of WVE-006 for alpha-1 antitrypsin deficiency (AATD). The data demonstrated successful RNA editing in humans, marking a significant milestone in the treatment of this inherited genetic disorder.